Use of Ceramide C16:0 and Ceramide Synthase 6 in the Treatment and Diagnosis of Multiple Sclerosis

The C16:0-ceramide biomarkers described here, allow both the diagnosis and monitoring of autoimmune disease multiple sclerosis. Moreover the ceramide synthase 6 (CerS6) outlined in this invention serves as target for the treatment of MS.

Further Information: PDF

INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Phone: +49 (0)69/2561632-0

Contact
Dr. Otmar Schöller

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors